Processa Pharmaceuticals, Inc. (PCSA) is progressing its Phase 2 study of NGC-Cap, a combination treatment of PCS6422 and Capecitabine, in patients with advanced or metastatic breast cancer.
The company recently completed enrollment of the 20th patient, part of a planned 90-patient study, a key milestone that sets the stage for the first formal interim analysis, which is expected to be completed in the first half of 2026.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.